Results 11 to 20 of about 4,616 (237)

Imbalance of Serum Bone-Metabolism-Related Factors Associated with Osteonecrosis of the Jaw [PDF]

Biomedicines
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse effect of bone-modifying agents. The aim of this study was to elucidate the pathogenesis of MRONJ through a comprehensive comparison of bone-metabolism-related factors ...
Kazuyuki Yusa, Yuji Takeda, Nobuyuki Sasahara, Tomoharu Hemmi, Shigeo Ishikawa, Tsuneo Konta   +5 more
doaj   +2 more sources

Comprehensive profiling of plasma and exosomal microRNAs in medication-related osteonecrosis of the jaw [PDF]

Scientific Reports
The role of circulating microRNAs (miRNAs) in the pathophysiology of medication-related osteonecrosis of the jaw (MRONJ) remains to be elucidated.
Sujin Oh, Minjae Park, Hyun Hwang, Jung-Hyun Park, Keun-Suh Kim, Jin-Woo Kim, Hyo-Jung Lee   +6 more
doaj   +2 more sources

Utility of quantitative standardized uptake value from pre-operative bone SPECT/CT for predicting post-surgical MRONJ healing response

EJNMMI Research
Background Medication-related osteonecrosis of the jaw (MRONJ) is a challenging condition often associated with long-term use of anti-resorptive medications.
Jung-Hyun Park, Da-Mi Yoon, Hai-Jeon Yoon, Jin-Woo Kim   +3 more
doaj   +2 more sources

Bone scintigraphy and positron emission tomography in the early diagnosis of MRONJ

Open Medicine
The aim of this study is to evaluate the bone scintigraphy (BS) and positron emission tomography (PET) in the early diagnosis of medication-related osteonecrosis of the jaws (MRONJ) and their possible use in the identification of patients at risk for ...
Pergolini Daniele, Mohsen Mohamed, Tenore Gianluca, Palaia Gaspare, Magnifico Lorenzo, Del Vecchio Alessandro, Romeo Umberto   +6 more
doaj   +2 more sources

Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy

Frontiers in Oral Health
Both denosumab (DMB) and bisphosphonates (BPs), antiresorptive drugs (ARDs) used for the treatment of osteoporosis and oncological disorders, are known for their potential to cause medication-related osteonecrosis of the jaws (MRONJ).
Dávid Száraz, Dávid Száraz, Vojtěch Peřina, Vojtěch Peřina, Jana Treglerová, Jana Treglerová, Ctirad Macháček, Ctirad Macháček, Ondřej Zendulka, Petra Bořilová Linhartová, Petra Bořilová Linhartová   +10 more
doaj   +2 more sources

MRONJ: comparison between two surgical approaches [PDF]

Dental Cadmos, 2021
Magda Mensi, Elisabetta Audino, Scotti Eleonora, Zanola Emanuele, Bettinsoli Elisa, Stefano Négrini, Luca Visconti, Stefano Salgarello   +7 more
  +6 more sources

Effect of metformin on inflammation and bone damage in a rat model of medication-related osteonecrosis of the jaw. [PDF]

Eur J Oral Sci
Abstract This study investigated how chronic metformin administration modulates the cellular profile and inflammatory markers in a zoledronic acid‐based rat model of medication‐related osteonecrosis of the jaw (MRONJ). Male Wistar rats were allocated to different treatments: (i) naïve, (ii) MRONJ (zoledronic acid, 0.2 mg/kg, i.v.
Rabelo LMA, Guimarães MV, Cajado AG, Lemos JVM, de Sousa FD, Alencar NMN, de Lima V, de Barros Silva PG, Alves APNN, Wong DVT, Lima-Júnior RCP.   +10 more
europepmc   +2 more sources

A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients

Scientific Reports, 2022
Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardized protocol for the prevention of denosumab induced medication-related osteonecrosis of the jaw (MRONJ) has not yet been established. The purpose of this
Seoyeon Jung, Jaeyeon Kim, Jin Hoo Park, Ki-Yeol Kim, Hyung Jun Kim, Wonse Park   +5 more
doaj   +1 more source

Novel Cell Therapy Using Mesenchymal Stromal Cell Sheets for Medication-Related Osteonecrosis of the Jaw

Frontiers in Bioengineering and Biotechnology, 2022
Despite medication-related osteonecrosis of the jaw (MRONJ) being first reported in 2003, the optimal treatment and prevention modalities for MRONJ are not clear.
Nobuyuki Kaibuchi, Nobuyuki Kaibuchi, Takanori Iwata, Takanori Iwata, Yoko Kawase Koga, Toshihiro Okamoto   +5 more
doaj   +1 more source

Review of: "Italian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ)" [PDF]

, 2023
Keisuke Seki
  +12 more sources